February 2016 in “Acta Medica Marisiensis” A woman with chronic hepatitis C had a rare skin condition linked to her illness.
27 citations
,
August 2010 in “Clinics in Dermatology” Hepatitis C virus can cause skin diseases and dermatologists play a crucial role in identifying these conditions.
3 citations
,
May 2009 in “Journal of Pediatric Gastroenterology and Nutrition” Consider infectious diseases like visceral leishmaniasis before diagnosing autoimmune hepatitis.
7 citations
,
September 1999 in “PubMed” Eating grouper fish liver can cause vitamin A poisoning with severe symptoms.
May 2021 in “Biomedical Journal of Indonesia” Lupus hepatitis can affect male SLE patients and is treatable with specific medications.
Patients with lichen planus should be tested for hepatitis C.
October 2011 in “The American Journal of Gastroenterology” Esomeprazole can cause hepatitis.
2 citations
,
February 2000 in “International Journal of Dermatology” Hepatitis C and alcohol abuse may lead to porphyria cutanea tarda.
May 2018 in “Dermatologic Surgery”
January 2021 in “Pediatric Oncall” Autoimmune hepatitis in children often affects girls and can be treated successfully with medication.
March 2016 in “International Journal of Infectious Diseases” Peginterferon alpha-2a effectively treats acute hepatitis C in hemodialysed patients, despite some side effects.
2 citations
,
July 2009 in “Mayo Clinic Proceedings” A 66-year-old woman with skin lesions and other symptoms improved after treatment for porphyria cutanea tarda.
June 2009 in “Mayo Clinic Proceedings” A woman was diagnosed with porphyria cutanea tarda and improved with phlebotomy and lifestyle changes.
36 citations
,
January 1993 in “Gut” High-dose interferon is effective for chronic hepatitis C but often causes flu-like symptoms.
27 citations
,
April 2005 in “Journal of Chemotherapy” Some patients may experience temporary total hair loss from hepatitis C treatment with PEG-interferon and ribavirin.
1 citations
,
December 2023 in “Curēus” Most children with a common hemochromatosis genotype had elevated iron levels but no severe symptoms.
37 citations
,
January 2010 in “Internal Medicine” A woman's liver was damaged by taking the herbal supplement Shou-Wu-Pian, but it got better after she stopped using it.
October 2020 in “The American journal of gastroenterology” Para-aminobenzoic acid in hair supplements can cause autoimmune hepatitis.
4 citations
,
August 2006 in “The Journal of Dermatology” HLA can be linked to autoimmune hepatitis.
17 citations
,
January 1993 in “Journal of Gastroenterology and Hepatology” Interferon α‐2b can temporarily reduce hepatitis C virus and normalize liver enzyme levels.
29 citations
,
January 2006 in “Clinical chemistry and laboratory medicine” SHBG binding properties are unchanged in male liver cirrhosis patients.
11 citations
,
August 1988 in “PubMed” Interferon therapy is a promising and safe treatment for hepatitis B in Southeast Asia.
16 citations
,
August 2002 in “Journal of Interferon and Cytokine Research” A man developed excessive hair growth after treatment with interferon-alpha and ribavirin for hepatitis C.
July 2024 in “The Egyptian Journal of Hospital Medicine” 34% of patients on hepatitis C treatment had reversible skin issues.
June 2016 in “Afro-Egyptian Journal of Infectious and Endemic Diseases” Most patients on this hepatitis C treatment experienced skin issues, especially hair loss.
17 citations
,
January 2011 in “The Korean Journal of Hepatology” Vogt-Koyanagi-Harada disease can develop during interferon therapy for chronic hepatitis C.
11 citations
,
April 2014 in “Journal of Clinical Virology” Older age, pre-existing skin conditions, cirrhosis, and pegylated interferon use increase the risk of skin issues during hepatitis C treatment.
2 citations
,
September 2024 in “Animal Cells and Systems” Hepatitis B virus alters steroid hormones in male mice, reducing dihydrotestosterone to inhibit viral replication.
November 2023 in “Gastroenterology” A woman with Budd-Chiari syndrome improved after treatment and needs a liver transplant, highlighting the importance of considering non-criteria antiphospholipid syndrome in similar cases.
October 2018 in “The American journal of gastroenterology” Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.